GKOS
Bearish signalScored 2026-10-11 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Glaukos Corporation
- Nom
- Glaukos Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $10.6B
- Employés
- 1,094
- PDG
- Thomas William Burns
- Site web
- https://www.glaukos.com
- Marché
- ALCBLCOEYPTIRIXOCULRXST
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 3 025 titres (~563 005,75 $ US)
- Insiders
- Kliman Gilbert HWEN LEANA
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$10,169,879
Avg sell (VWAP, 90d window) $180.09 vs last close $164.84 (-8.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,822,690 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-19
- Liquidity
- Liquid $168,156,696/day · 20d vol
- Last synced
-
2026-10-16 21:10:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-05 | Navratil Tomas | Sell · S · 10b5-1 | 312 | $165.60 | $51,667 | Form 4 |
| 2026-09-25 | Navratil Tomas | Sell · S · 10b5-1 | 1,083 | $154.88 | $167,735 | Form 4 |
| 2026-09-16 | Navratil Tomas | Sell · S · 10b5-1 | 4 | $172.00 | $688 | Form 4 |
| 2026-08-28 | Navratil Tomas | Sell · S | 10 | $182.50 | $1,825 | Form 4 |
| 2026-08-19 | Kliman Gilbert H | Sell · S | 2,500 | $190.00 | $475,000 | Form 4 |
| 2026-08-11 | Gilliam Joseph E | Sell · S | 32,037 | $180.49 | $5,782,358 | Form 4 |
| 2026-08-07 | Thurman Alex R. | Sell · S · 10b5-1 | 20,000 | $180.13 | $3,602,600 | Form 4 |
| 2026-07-31 | WEN LEANA | Sell · S | 525 | $167.63 | $88,006 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-11 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
GKOS presents a meaningful earnings catalyst backed by strong iDose TR revenue growth, raised guidance, and fresh institutional sponsorship, supporting a moderate event-driven opportunity.
The first sentence of the analysis written for GKOS on 2026-10-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 4.69 · operating margin -17% — readings disagree
Suggested stop 152.03, nearest stored support minus 0.5 ATR(7.8% under the last close). Reward/risk to the next stored resistance is 1.50. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 77.5% | 75.5% | 76.0% | 75.6% | 77.3% | |
| Ebit Margin | -37.1% | -35.4% | -38.2% | -29.9% | -12.2% | |
| Ebitda Margin | -28.8% | -24.9% | -26.1% | -17.2% | -0.5% | |
| Operating Profit Margin | -17.1% | -31.9% | -40.9% | -29.1% | -11.2% | |
| Pretax Profit Margin | -38.0% | -38.0% | -42.5% | -34.8% | -16.8% | |
| Continuous Operations Profit Margin | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | |
| Net Profit Margin | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | |
| Bottom Line Profit Margin | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | |
| Current Ratio | 4.690 | 5.987 | 5.343 | 6.134 | 7.672 | |
| Quick Ratio | 4.062 | 5.219 | 4.776 | 5.611 | 7.309 | |
| Solvency Ratio | -0.612 | -0.512 | -0.202 | -0.116 | -0.028 | |
| Cash Ratio | 0.897 | 2.258 | 1.263 | 1.652 | 1.589 | |
| Price To Earnings Ratio | -34.424 | -54.130 | -28.594 | -20.900 | -41.533 | |
| Price To Earnings Growth Ratio | -1.870 | 150.481 | -0.866 | -0.219 | 0.688 | |
| Forward Price To Earnings Growth Ratio | -1.870 | 150.481 | -0.866 | -0.219 | 0.688 | |
| Price To Earnings Diluted Ratio | -34.424 | -54.130 | -28.594 | -20.900 | -41.533 | |
| Price To Earnings Diluted Growth Ratio | -1.870 | 150.481 | -0.866 | -0.219 | 0.688 | |
| Price To Book Ratio | 9.841 | 10.314 | 8.337 | 3.910 | 3.514 | |
| Price To Sales Ratio | 12.725 | 20.627 | 12.233 | 7.326 | 7.017 | |
| Price To Free Cash Flow Ratio | -119.567 | -116.982 | -49.354 | -32.714 | -89.398 | |
| Price To Operating Cash Flow Ratio | -139.347 | -129.001 | -66.656 | -62.641 | 83.497 | |
| Debt To Assets Ratio | 0.156 | 0.106 | 0.408 | 0.356 | 0.340 | |
| Debt To Equity Ratio | 0.213 | 0.135 | 0.831 | 0.722 | 0.653 | |
| Debt To Capital Ratio | 0.175 | 0.119 | 0.454 | 0.419 | 0.395 | |
| Long Term Debt To Capital Ratio | 0.052 | 0.000 | 0.380 | 0.347 | 0.323 | |
| Financial Leverage Ratio | 1.362 | 1.271 | 2.037 | 2.027 | 1.923 | |
| Working Capital Turnover Ratio | 1.356 | 1.102 | 0.908 | 0.712 | 0.698 | |
| Operating Cash Flow Ratio | -0.458 | -0.816 | -0.780 | -0.457 | 0.390 | |
| Operating Cash Flow Sales Ratio | -0.091 | -0.160 | -0.184 | -0.117 | 0.084 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.165 | 1.103 | 1.351 | 1.915 | -0.934 | |
| Debt Service Coverage Ratio | -30.358 | -9.603 | -6.092 | -3.500 | -0.125 | |
| Interest Coverage Ratio | -18.713 | -12.188 | -9.440 | -5.999 | -2.458 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -76.937 | 24.463 | |
| Operating Cash Flow Coverage Ratio | -0.332 | -0.593 | -0.151 | -0.086 | 0.064 | |
| Capital Expenditure Coverage Ratio | -6.045 | -9.733 | -2.853 | -1.093 | 0.517 | |
| Dividend Paid And Capex Coverage Ratio | -6.045 | -9.733 | -2.853 | -1.093 | 0.517 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -44.544 | -82.015 | -50.419 | -47.900 | -1,591.394 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 77.5% | ▲2.0% | ▲1.1% |
| Ebit Margin | -37.1% | ▼-1.8% | ▼-6.6% |
| Ebitda Margin | -28.8% | ▼-3.8% | ▼-9.3% |
| Operating Profit Margin | -17.1% | ▲14.8% | ▲8.9% |
| Pretax Profit Margin | -38.0% | ▼-0.1% | ▼-4.0% |
| Continuous Operations Profit Margin | -37.0% | ▲1.2% | ▼-3.0% |
| Net Profit Margin | -37.0% | ▲1.2% | ▼-3.0% |
| Bottom Line Profit Margin | -37.0% | ▲1.2% | ▼-3.0% |
| Current Ratio | 4.690 | ▼-1.297 | ▼-1.275 |
| Quick Ratio | 4.062 | ▼-1.157 | ▼-1.333 |
| Solvency Ratio | -0.612 | ▼-0.100 | ▼-0.318 |
| Cash Ratio | 0.897 | ▼-1.361 | ▼-0.635 |
| Price To Earnings Ratio | -34.424 | ▲19.706 | ▲1.492 |
| Price To Earnings Growth Ratio | -1.870 | ▼-152.351 | ▼-31.512 |
| Forward Price To Earnings Growth Ratio | -1.870 | ▼-152.351 | ▼-31.512 |
| Price To Earnings Diluted Ratio | -34.424 | ▲19.706 | ▲1.492 |
| Price To Earnings Diluted Growth Ratio | -1.870 | ▼-152.351 | ▼-31.512 |
| Price To Book Ratio | 9.841 | ▼-0.473 | ▲2.658 |
| Price To Sales Ratio | 12.725 | ▼-7.902 | ▲0.740 |
| Price To Free Cash Flow Ratio | -119.567 | ▼-2.585 | ▼-37.964 |
| Price To Operating Cash Flow Ratio | -139.347 | ▼-10.346 | ▼-76.517 |
| Debt To Assets Ratio | 0.156 | ▲0.050 | ▼-0.117 |
| Debt To Equity Ratio | 0.213 | ▲0.078 | ▼-0.298 |
| Debt To Capital Ratio | 0.175 | ▲0.057 | ▼-0.137 |
| Long Term Debt To Capital Ratio | 0.052 | ▲0.052 | ▼-0.169 |
| Financial Leverage Ratio | 1.362 | ▲0.091 | ▼-0.362 |
| Working Capital Turnover Ratio | 1.356 | ▲0.254 | ▲0.401 |
| Operating Cash Flow Ratio | -0.458 | ▲0.359 | ▼-0.033 |
| Operating Cash Flow Sales Ratio | -0.091 | ▲0.069 | ▲0.002 |
| Free Cash Flow Operating Cash Flow Ratio | 1.165 | ▲0.063 | ▲0.245 |
| Debt Service Coverage Ratio | -30.358 | ▼-20.756 | ▼-20.423 |
| Interest Coverage Ratio | -18.713 | ▼-6.525 | ▼-8.953 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲10.495 |
| Operating Cash Flow Coverage Ratio | -0.332 | ▲0.261 | ▼-0.112 |
| Capital Expenditure Coverage Ratio | -6.045 | ▲3.688 | ▼-2.204 |
| Dividend Paid And Capex Coverage Ratio | -6.045 | ▲3.688 | ▼-2.204 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -44.544 | ▲37.471 | ▲318.711 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.46B | $7.91B | $3.85B | $2.07B | $2.06B | |
| Enterprise value | $6.51B | $7.84B | $4.14B | $2.34B | $2.35B | |
| EV / Sales | 12.82x | 20.45x | 13.16x | 8.26x | 7.98x | |
| EV / Op. cash flow | -140.40x | -127.92x | -71.68x | -70.60x | 94.94x | |
| EV / Free cash flow | -120.47x | -116.00x | -53.08x | -36.87x | -101.65x | |
| EV / EBITDA | -44.54x | -82.02x | -50.42x | -47.90x | -1591.39x | |
| Net debt / EBITDA | -0.33x | 0.69x | -3.54x | -5.40x | -191.78x | |
| Current ratio | 4.69x | 5.99x | 5.34x | 6.13x | 7.67x | |
| Income quality | 0.35x | 0.42x | 0.43x | 0.33x | -0.50x | |
| Graham net-net | $3 | $4 | -$3 | -$3 | -$2 | |
| Tax burden | 97.2% | 100.5% | 100.7% | 100.8% | 100.7% | |
| Interest burden | 102.5% | 107.4% | 111.4% | 116.2% | 137.3% | |
| Working capital | $373.7M | $374.7M | $321.4M | $371.5M | $422.8M | |
| Invested capital | $766.5M | $874.2M | $845.1M | $912.3M | $967.8M | |
| Return on assets | -21.0% | -15.0% | -14.3% | -9.2% | -4.4% | |
| Operating ROA | -9.3% | -12.8% | -12.8% | -7.5% | -3.1% | |
| Return on tangible assets | -27.4% | -22.7% | -22.8% | -14.2% | -6.8% | |
| Return on equity | -28.6% | -19.1% | -29.2% | -18.7% | -8.4% | |
| Return on invested capital | -10.6% | -13.6% | -14.9% | -8.2% | -3.1% | |
| Return on capital employed | -10.9% | -13.6% | -14.9% | -8.2% | -3.1% | |
| Earnings yield | -2.9% | -1.9% | -3.5% | -4.8% | -2.4% | |
| Free cash flow yield | -0.8% | -0.9% | -2.0% | -3.1% | -1.1% | |
| Capex / Op. cash flow | -16.5% | -10.3% | -35.1% | -91.5% | 193.4% | |
| Capex / Depreciation | 20.1% | 15.8% | 53.3% | 84.2% | 138.8% | |
| Capex / Sales | 1.5% | 1.6% | 6.4% | 10.7% | 16.3% | |
| SG&A / Sales | 64.9% | 68.5% | 71.2% | 68.2% | 61.0% | |
| R&D / Sales | 29.7% | 35.6% | 44.1% | 43.6% | 34.4% | |
| Stock comp / Sales | 12.5% | 13.1% | 13.8% | 13.6% | 10.3% | |
| Intangibles / Total assets | 23.3% | 33.8% | 37.1% | 34.8% | 35.3% | |
| Days sales outstanding | 78d | 58d | 46d | 47d | 42d | |
| Days payables outstanding | 79d | 51d | 65d | 76d | 40d | |
| Operating cycle | 281d | 282d | 249d | 247d | 168d | |
| Cash conversion cycle | 203d | 231d | 184d | 171d | 127d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-24 61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier''s stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the
- 2026-08-20 GKOS Stock Surges 67% Year to Date: What''s Driving the Rally? Glaukos'' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
- 2026-08-19 Here''s Why You Should Retain Glaukos Stock in Your Portfolio for Now Glaukos'' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
- 2026-08-19 Glaukos Announces Participation in Wells Fargo Healthcare Conference ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors.
- 2026-08-13 Which Small-Cap ETF Is the Better Buy: iShares'' Growth-Focused IWO or Invesco''s Revenue-Weighted RWJ? Small-cap stocks are surging, but how you own them matters more than most investors realize.
- 2026-08-05 First Trust Advisors LP Acquires 40,798 Shares of Glaukos Corporation $GKOS First Trust Advisors LP increased its holdings in Glaukos Corporation (NYSE: GKOS) by 2,085.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,754 shares of the medical instruments supplier''s stock after buying an additional 40,798 shares
- 2026-07-30 Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up GKOS'' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.
- 2026-07-30 Glaukos Q2 Earnings Call Highlights Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management''s expectations.
- 2026-07-29 Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-07-29 Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript